Cure8 research brief
Antibiotics can substantially change gut microbes; for people with IBD those changes may affect inflammation and gut barrier function. The review summarizes microbiome-targeted strategies that patients and clinicians may encounter.
People with IBD (including ulcerative colitis), clinicians who prescribe antibiotics or manage IBD, and researchers studying the gut microbiome or microbiome-based therapies.
The article is a review focused on antibiotic-induced dysbiosis and its links to metabolic and immune dysfunction in IBD, with discussion of effects on gut barrier function and inflammatory pathways.
It lists microbial shifts seen in IBD (for example increases in Proteobacteria and decreases in taxa such as Roseburia, Bifidobacterium, and Akkermansia) and describes how loss of beneficial metabolites may relate to inflammation.
The review surveys current and emerging interventions to rebalance the microbiome — including probiotics, prebiotics, fecal microbiota transplantation, dietary strategies, lifestyle modification, and antibiotic stewardship — and notes important gaps such as strain-specific effects, individualized responses, and long-term safety.
This brief is grounded in the article abstract provided by the journal (structured content depth: abstract). It summarizes the review's scope rather than presenting new trial results or clinical recommendations.
This record is a review article (abstract-based summary). It synthesizes existing studies and highlights research gaps; it does not report new clinical trial results. Details about specific interventions, efficacy, and safety depend on individual studies cited in the full paper.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial tests whether adding nitazoxanide—an antiparasitic with reported antimicrobial and anti-inflammatory effects—can improve symptoms in people with mild-to-moderate ulcerative colitis. If effective, it could...
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
Intestinal barrier dysfunction is a likely driver of inflammation and flares in ulcerative colitis, so therapies that restore barrier integrity could help reduce disease activity and recurrence. This review highlights...
